Future medical prospects for Sandostatin.

[1]  M. Langman.  Pharmacotherapy of bleeding peptic ulcers--is it time to give up the search? , 1990, Gastroenterology.

[2]  J. Christiansen,et al.  Acute Effects of a Somatostatin Analogue on Kidney Function in Type 1 Diabetic Patients , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[3]  A. Harris,et al.  Effect of the Long‐Acting Somatostatin Analogue SMS 201‐995 on Growth Rate and Reduction of Predicted Adult Height in Ten Tall Adolescents , 1990, Acta paediatrica Scandinavica.

[4]  P. Hindmarsh,et al.  A PRELIMINARY REPORT ON THE ROLE OF SOMATOSTATIN ANALOGUE (SMS 201‐995) IN THE MANAGEMENT OF CHILDREN WITH TALL STATURE , 1990, Clinical endocrinology.

[5]  C. Mathias,et al.  Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes. , 1989, Clinical science.

[6]  J. Christiansen,et al.  Placebo-controlled trial with the somatostatin analogue SMS 201-995 in peptic ulcer bleeding. , 1989, Gastroenterology.

[7]  M. M. Cooper,et al.  Successful treatment of a high-output fistula with a somatostatin analogue following pancreas transplantation. , 1989, Transplantation proceedings.

[8]  K. Forde,et al.  Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. , 1989, Surgery.

[9]  K. Ladefoged,et al.  Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome. , 1989, Gut.

[10]  C. Polychronakos,et al.  Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. , 1989, Anticancer research.

[11]  M. Gil,et al.  Treatment of 27 Postoperative Enterocutaneous Fistulas with the Long Half‐life Somatostatin Analogue SMS 201–995 , 1989, Annals of surgery.

[12]  R. Hoeldtke,et al.  Effect of the somatostatin analogue SMS-201-995 on the adrenergic response to glucose ingestion in patients with postprandial hypotension. , 1989, The American journal of medicine.

[13]  W. Malarkey,et al.  Metabolic Effects of Long-Acting Somatostatin Analogue (Sandostatin) in Type I Diabetic Patients on Conventional Therapy , 1989, Diabetes.

[14]  G. Pagani,et al.  Effects of a somatostatin derivative (SMS 201–995) on postprandial hyperglycemia in insulin-dependent diabetics studied by means of a closed-loop device , 1989, Journal of endocrinological investigation.

[15]  R. Hoeldtke,et al.  Treatment of orthostatic hypotension with octreotide. , 1989, The Journal of clinical endocrinology and metabolism.

[16]  W. Hoefnagels,et al.  Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly. , 1989, The Journal of clinical endocrinology and metabolism.

[17]  E. P. Krenning,et al.  LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN , 1989, The Lancet.

[18]  R. Comtois,et al.  Clinical pancreas transplantation: a learning curve of its management. , 1989, Transplantation proceedings.

[19]  E. Kohner,et al.  Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. , 1989, Acta endocrinologica.

[20]  E. Robinson,et al.  SMS 201-995, a somatostatin analogue, and diarrhea in the acquired immunodeficiency syndrome (AIDS) , 1988, Annals of internal medicine.

[21]  O. Garden,et al.  The effect of a long‐acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis , 1988, Alimentary pharmacology & therapeutics.

[22]  M. Rudin,et al.  Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). , 1988, Cancer research.

[23]  K. Suh,et al.  Effect of SMS 201–995 in Rapidly Progressive Diabetic Retinopathy , 1988, Diabetes Care.

[24]  S. Kunjara,et al.  The effect of a somatostatin analogue (SMS 201-995, Sandostatin) on the concentration of phosphoribosyl pyrophosphate and the activity of the pentose phosphate pathway in the early renal hypertrophy of experimental diabetes in the rat. , 1988, Biochemical medicine and metabolic biology.

[25]  H. Nagasawa,et al.  Counteraction by combined treatment with high dose of oestrogen and somatostatin of mammary growth suppression in mice. , 1988, In vivo.

[26]  E. Chilvers,et al.  Postprandial Glycaemic Effects of a Long-Acting Somatostatin Analogue (Octreotide) in Non-Insulin Dependent Diabetes Mellitus , 1988, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[27]  B. Erstad,et al.  Treatment of Severe Cryptosporidium-Related Diarrhea with Octreotide in a Patient with AIDS , 1988, Drug intelligence & clinical pharmacy.

[28]  A. Harris,et al.  Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. , 1987, Acta endocrinologica. Supplementum.

[29]  M. Ziegler,et al.  Treatment of diabetic diarrhea and orthostatic hypotension with somatostatin analogue SMS 201-995. , 1987, The American journal of medicine.

[30]  S. Bloom,et al.  Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. , 1987, British medical journal.

[31]  G. Giustina,et al.  SMS 201-995 Improves Glucose Tolerance in Insulin-Treated Type II Diabetic Patients , 1987, Diabetes Care.

[32]  J. Foekens,et al.  Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. , 1987, Cancer research.

[33]  I. Jackson,et al.  Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). , 1986, Annals of internal medicine.

[34]  M. S. Ríos,et al.  Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. , 1986, The Journal of clinical endocrinology and metabolism.

[35]  G. Spinas,et al.  Reduced Postprandial Hyperglycemia After Subcutaneous Injection of a Somatostatin-Analogue (SMS 201-995) in Insulin-dependent Diabetes Mellitus , 1985, Diabetes Care.

[36]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[37]  R. McKee,et al.  A study of octreotide in oesophageal varices. , 1990, Digestion.

[38]  B. Zinman,et al.  The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. , 1989, The Journal of clinical endocrinology and metabolism.

[39]  A. Harris,et al.  Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. , 1989, Anticancer research.

[40]  J. Biller,et al.  Successful treatment of idiopathic secretory diarrhea of infancy with the somatostatin analogue SMS 201-995. , 1988, Gastroenterology.

[41]  G. Poston,et al.  Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. , 1988, American journal of surgery.

[42]  J. Pickleman,et al.  Treatment of pancreatic cutaneous fistulas with a somatostatin analog. , 1988, American journal of surgery.

[43]  K. Buchheit,et al.  Chemical Structure, Pharmacodynamic Profile and Pharmacokinetics of SMS 201–995 (Sandostatin ® ) , 1988 .